Latest news with #BrettCohen
Yahoo
3 days ago
- Health
- Yahoo
Recovery Centers of America Earns National Recognition on Newsweek's 2025 Best Treatment Centers List
RCA Named Among America's Best, Reflecting Commitment to Lifesaving Addiction Care KING OF PRUSSIA, Pa., Aug. 8, 2025 /PRNewswire/ -- Recovery Centers of America (RCA), a nationally recognized leader in evidence-based addiction treatment, is proud to announce that it has been awarded on Newsweek's 2025 list of America's Best Addiction Treatment Centers. The prestigious annual ranking, developed in partnership with Statista Inc., world-leading statistics portal and industry ranking provider, highlights the top inpatient and residential addiction treatment centers nationwide based on quality of care, professional reputation, and patient experience. "At Recovery Centers of America, we are driven by a singular mission: to save one million lives impacted by substance use and mental health disorders, one person at a time," said Brett Cohen, chief executive officer of Recovery Centers of America. "To see RCA recognized by Newsweek affirms the dedication of our clinical teams, the strength of our treatment model, and our deep commitment to patients and families across the country. We're honored to be a trusted resource to those in their recovery journey." Newsweek's rankings were determined by a combination of accreditation data from the Substance Abuse and Mental Health Services Administration (SAMHSA), peer reputation surveys from medical professionals, and Google review scores measuring patient satisfaction. With more than 17,000 addiction treatment facilities across the U.S., earning placement among the top 420 reflects RCA's unwavering commitment to high-quality treatment, compassionate support, and long-term recovery success. RCA offers comprehensive, evidence-based treatment for substance use disorders and co-occurring mental health disorders, including inpatient treatment—medically monitored detox and residential—outpatient services like PHP, IOP, Recovery Living, family coaching and education, and a robust alumni network and case management program to recovery last well beyond their doors. All RCA sites are fully accredited and designed to provide care in a comfortable, stigma-free environment. To learn more about Recovery Centers of America visit or to view the full list of Newsweek's 2025 honorees, visit About Recovery Centers of AmericaRecovery Centers of America (RCA) is on a mission to save one million lives impacted by addiction and mental health disorders, one person at a time. RCA's evidence-based care approach features a full continuum of consistent, personalized, inpatient and outpatient services at world-class facilities in the Northeast, Mid-Atlantic, Midwest and Southeast regions. These programs are designed to support lasting recovery and lifelong healing. RCA admits patients 24/7, accepts most major insurances, and provides transportation, intervention and family support services. RCA is recognized in Newsweek's America's Best Addiction Centers rankings for excellence. For inquiries or admissions, call 1-844-5-RCA-NOW (844-572-2669). View original content to download multimedia: SOURCE Recovery Centers of America
Yahoo
09-06-2025
- Business
- Yahoo
Dilon Technologies, Inc. Closes $9 Million in Growth Capital Financing
NEWPORT NEWS, Va., June 9, 2025 /PRNewswire/ -- Dilon Technologies®, a global leader in medical devices for biosurgery and breast cancer treatment and diagnosis, today announced a $9 million growth capital investment from JGB Management Inc. The investment will support Dilon's continued double-digit revenue growth and operational scaling. Dilon Technologies has built a robust presence in surgical settings with a portfolio of products that improve clinical outcomes. "We are proud to partner with JGB as we advance our mission to deliver evidence-based surgical solutions worldwide," said George Makhoul, CEO of Dilon Technologies. "This funding empowers us to continue delivering best-in-class innovations that improve patient care." HEMOBLAST Bellows® is a groundbreaking advanced hemostatic agent used in a wide range of surgeries—including cardiac, general, and orthopedic procedures. It remains the only FDA-approved product specifically indicated for the control of minimal, mild, and moderate bleeding. Now utilized in several hundred U.S. hospitals, HEMOBLAST® Bellows continues to redefine standards in surgical hemostasis. Another key product, MarginProbe® an in-surgery, real-time breast cancer margin assessment device. It enables surgeons to assess lumpectomy margins intraoperatively, significantly reducing the need for repeat surgeries. Clinical studies show MarginProbe® reduces re-excision rates by 25% to 80%. A 2025 study published in The American Surgeon Journal highlighted a 42% reduction in re-excision for patients with DCIS. A next-generation version of the device has been submitted to the FDA, with approval anticipated by year-end. Dilon's Navigator™ Gamma Probe product line, a market-leading tool for radio-guided lymphatic mapping and tumor localization, continues to perform strongly worldwide. A new, enhanced version is expected to launch by late 2025. "We are pleased to partner with Dilon Technologies to help them grow in their mission to provide surgical solutions worldwide," said Brett Cohen, CEO of JGB Management Inc. For more information, visit About Dilon Technologies® Technologies® Inc. is a commercial-stage medical device company that develops, manufactures, and markets innovative technologies used in hemostasis, cancer detection and assessment, and airway management. Dilon's growing surgical portfolio includes: HEMOBLAST Bellows®: The only FDA-approved powder-form hemostatic agent for minimal, mild, and moderate bleeding. MarginProbe®: A groundbreaking real-time margin assessment tool for breast cancer surgery. Navigator™ System: A leading surgical gamma probe for tumor localization and lymphatic mapping. TrueView 100 Pro: A surgical specimen analyzer for intraoperative use. CoPilot VL+®: A compact, portable video laryngoscope for airway visualization. About JGB Management Inc. JGB Management Inc., founded by Brett Cohen in 2005, is an alternative asset management firm focused on investing in niche credit-oriented situations. JGB specializes in privately negotiated investments. The firm is based in Westport CT. View original content to download multimedia: SOURCE Dilon Technologies Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-06-2025
- Business
- Yahoo
Dilon Technologies, Inc. Closes $9 Million in Growth Capital Financing
NEWPORT NEWS, Va., June 9, 2025 /PRNewswire/ -- Dilon Technologies®, a global leader in medical devices for biosurgery and breast cancer treatment and diagnosis, today announced a $9 million growth capital investment from JGB Management Inc. The investment will support Dilon's continued double-digit revenue growth and operational scaling. Dilon Technologies has built a robust presence in surgical settings with a portfolio of products that improve clinical outcomes. "We are proud to partner with JGB as we advance our mission to deliver evidence-based surgical solutions worldwide," said George Makhoul, CEO of Dilon Technologies. "This funding empowers us to continue delivering best-in-class innovations that improve patient care." HEMOBLAST Bellows® is a groundbreaking advanced hemostatic agent used in a wide range of surgeries—including cardiac, general, and orthopedic procedures. It remains the only FDA-approved product specifically indicated for the control of minimal, mild, and moderate bleeding. Now utilized in several hundred U.S. hospitals, HEMOBLAST® Bellows continues to redefine standards in surgical hemostasis. Another key product, MarginProbe® an in-surgery, real-time breast cancer margin assessment device. It enables surgeons to assess lumpectomy margins intraoperatively, significantly reducing the need for repeat surgeries. Clinical studies show MarginProbe® reduces re-excision rates by 25% to 80%. A 2025 study published in The American Surgeon Journal highlighted a 42% reduction in re-excision for patients with DCIS. A next-generation version of the device has been submitted to the FDA, with approval anticipated by year-end. Dilon's Navigator™ Gamma Probe product line, a market-leading tool for radio-guided lymphatic mapping and tumor localization, continues to perform strongly worldwide. A new, enhanced version is expected to launch by late 2025. "We are pleased to partner with Dilon Technologies to help them grow in their mission to provide surgical solutions worldwide," said Brett Cohen, CEO of JGB Management Inc. For more information, visit About Dilon Technologies® Technologies® Inc. is a commercial-stage medical device company that develops, manufactures, and markets innovative technologies used in hemostasis, cancer detection and assessment, and airway management. Dilon's growing surgical portfolio includes: HEMOBLAST Bellows®: The only FDA-approved powder-form hemostatic agent for minimal, mild, and moderate bleeding. MarginProbe®: A groundbreaking real-time margin assessment tool for breast cancer surgery. Navigator™ System: A leading surgical gamma probe for tumor localization and lymphatic mapping. TrueView 100 Pro: A surgical specimen analyzer for intraoperative use. CoPilot VL+®: A compact, portable video laryngoscope for airway visualization. About JGB Management Inc. JGB Management Inc., founded by Brett Cohen in 2005, is an alternative asset management firm focused on investing in niche credit-oriented situations. JGB specializes in privately negotiated investments. The firm is based in Westport CT. View original content to download multimedia: SOURCE Dilon Technologies Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
